real-time news and commentary for investors
Thursday, Aug 29
Pfizer completes community vaccine trials for Prevenar
- Pfizer (PFE +0.8%) says it's completed pneumonia case accrual data in a trial of patients over 65 to evaluate whether Prevenar 13 is effective in preventing community-acquired pneumonia cause by 12 pneumococcal strains included in the vaccine.
- The trial, which involves about 85,000 people, was needed to fulfil regulatory commitments under the FDA's accelerated approval program.